<DOC>
	<DOC>NCT00359476</DOC>
	<brief_summary>The purpose of this study is to learn if vinflunine can shrink or slow the growth of cancer in patients with advanced or metastatic stomach cancer who have progressed on a prior treatment with a fluoropyrimidine or taxane-containing chemotherapy regimen. The safety of this treatment will also be studied.</brief_summary>
	<brief_title>A Study of Vinflunine in Patients With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Patients with locally advanced or metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction who have progressed on a fluoropyrimidine or taxanecontaining regimen in any combination in one prior first line treatment. EGOC performance status of 0,1 or 2 Men and women, 18 years of age and older Patients having received more than one previous systemic chemotherapy regimen in any setting. Major abdominal surgery within 2 months or any other surgery under general anesthesia within 4 weeks Unresolved occlusive or subocclusive intestinal disease or any significant chronic intestinal disease (e.g. ulcerative colitis) Prior radiation to &gt;=30% of the bone marrow and/or radiation within 4 weeks prior to enrollment Acute or chronic hepatitis Known HIV infection A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval &gt;450 ms A history of additional risk factors for Torsade de Pointes (e.g., heart failure hypokalemia, family history of Long QT Syndrome)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Locally advanced/metastatic gastric adenocarcinoma</keyword>
	<keyword>adenocarcinoma-gastroesophageal junction</keyword>
	<keyword>Gastric Adenocarcinoma</keyword>
</DOC>